Detalhe da pesquisa
1.
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Lancet Oncol
; 22(11): 1530-1540, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656227
2.
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Infect Dis
; 23(2): 183-195, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36272432
3.
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Nat Commun
; 13(1): 7284, 2022 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36435798